Loading…

Placenta accreta risk—antepartum score in predicting clinical outcomes of placenta accreta spectrum: A multicenter validation study

Objective To validate the use of placenta accreta risk—antepartum (PAR‐A) score as a predictive tool of clinical outcomes of placenta accreta spectrum (PAS). Methods This is a prospective study, conducted in six PAS specialized centers in six different countries. The study was conducted between Octo...

Full description

Saved in:
Bibliographic Details
Published in:International journal of gynecology and obstetrics 2022-08, Vol.158 (2), p.424-431
Main Authors: Shazly, Sherif A., Anan, Mohamed A., Makukhina, Tatiana B., Melekoglu, Rauf, Ahmed, Farhat ul A., Pinto, Pedro V., Takahashi, Hironori, Ahmed, Nermeen B., Sayed, Esraa G., Elassall, Gena M., Said, Aliaa E., Fahmy, Mohamed S., Dawyee, Diaa M., Penzhoyan, Gregory A., Amirkhanyan, Arpine M., Yılmaz, Ercan, Celik, Nesibe Z., Aziz, Hijab, Akhter, Tayyaba, Ambreen, Afshan, Abdelbadie, Amr S.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To validate the use of placenta accreta risk—antepartum (PAR‐A) score as a predictive tool of clinical outcomes of placenta accreta spectrum (PAS). Methods This is a prospective study, conducted in six PAS specialized centers in six different countries. The study was conducted between October 1, 2020 and March 31, 2021. Women who were provisionally diagnosed with PAS during pregnancy were considered eligible. A machine‐learning‐based PAR‐A score was calculated. Diagnostic performance of the PAR‐A score was evaluated using a receiver operating characteristic curve, for perioperative massive blood loss and admission to intensive care unit (ClinicalTrials.gov identifier NCT04525001). Results Of 97 eligible women, 86 were included. PAS‐associated massive blood loss occurred in 10 patients (11.63%). Median PAR‐A scores of massive blood loss in the current cohort were 8.9 (interquartile range 6.9–14.1). In predicting massive blood loss, the area under the curve of PAR‐A scores was 0.85 (95% confidence interval [CI] 0.74–0.95), which was not significantly different from the original cohort (P = 0.2). PAR‐A score prediction of intensive care unit admission was slightly higher compared with the original cohort (0.88, 95% CI 0.81–0.95; P = 0.06). Conclusion PAR‐A score is a novel scoring system of PAS outcomes, which showed external validity based on current data. PAR‐A score is a validated tool that can predict clinical outcomes prenatally in women with placenta accreta spectrum.
ISSN:0020-7292
1879-3479
DOI:10.1002/ijgo.13993